STEEPER
In their centenary year Steeper Group, a world leading manufacturer of prosthetic devices, launch their latest myoelectric system. The full limb build is designed to offer patients and clinicians across the globe a durable, high-capacity upper limb system at an affordable cost, which harnesses the power of popular myoelectric technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005522/en/
Designed for the everyday, the Steeper Myoelectric System includes the new Myo Kinisi hand which provides an easy to control, high-speed grasp alongside a strong grip force to carry out activities of daily living with ease, with the added benefit of an Auto-Grip function allowing users a more secure grip on difficult to hold objects. The hand is complemented by advanced myoelectrodes for increased accuracy and gain control, and is powered by the all new high-capacity S-Charge System which features a 3500mAh internal battery, making it one of the most powerful available. The prosthesis is finished by the ‘Elegance Plus’ cosmetic glove, designed specifically to complement the Myo Kinisi.
Paul Steeper, CEO of Steeper Group and SteeperUSA commented “a new myoelectric system is something our customers have desired for some time. We’ve used our innovative knowledge of upper limb prostheses to deliver an evolution to a myoelectric system; using the latest advancements in product design, super capacitor technology and modern materials such as titanium for increased strength.”
Patients will enjoy the enhanced cosmesis given by the Elegance Plus silicone glove which has been designed to work in harmony with the Myo Kinisi. An internal reinforced mesh layer increases durability for even high activity users, and improved realism to the skin appearance is achieved with enhancement on the knuckles, joints and nail finish; the Elegance Plus Glove is available in 19 TrueFinishTM shades.
Clinicians can program the Myo Kinisi to meet exacting patient preferences with a choice of five modes and fine adjustments to control parameters can be made via the Steeper Configuration Device, a simple three button operation programming hub with an easy-to-read screen.
Paul Steeper concluded “the Steeper Myoelectric System will offer both clinicians and users a greater choice of durable, reliable and easy to use devices. The Myo Kinisi offers superb grip strength via trusted technology and the Elegance Plus Glove is sure appeal to a wide range of users with its enhanced finish and skin-like texture; couple that with our very latest myoelectrodes and increased capacity S-Charge battery system and users will instantly benefit from these innovations. Patient trials have proved successful with users commenting on the increased control the Myo Kinisi offers whilst using a control strategy they are already familiar with; meaning the hand is easily and readily usable.”
ENDS
Notes to editors:
Steeper Group trade as SteeperUSA within the United States and Canada.
For more information on the Steeper Myoelectric System or any of our upper limb prosthetic products, please visit www.steepergroup.com or www.steeperusa.com .
Image caption: The Steeper Upper Limb Build offers a secure grip, an enhanced cosmetic appearance and is powered by one of the most powerful battery systems on the market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005522/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 14:00:00 CEST | Press release
New instrument automates tissue processing for researchers in cancer, immunology and other science fields To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom